Eurifel RCP FeLV


vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Eurifel RCP FeLV has not been renewed by the marketing authorisation holder and is now withdrawn.

This EPAR was last updated on 23/07/2004

Authorisation details

Product details
Eurifel RCP FeLV
Agency product number
Active substance
  • canarypox virus expressing feline leukemia virus, live
  • feline calicivirus, strain 255, inactivated
  • feline panleucopenia virus, strain PLI IV, live
  • feline rhinotracheitis virus, strain C27, antigen
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Date of issue of marketing authorisation valid throughout the European Union
Contact address
29, avenue Tony Garnier
69007 Lyon

Product information

23/07/2004 Eurifel RCP FeLV - EMEA/V/C/000067 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.

Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus.

The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.

How useful was this page?

Add your rating
1 rating